Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies

被引:0
|
作者
O'Donovan, Alexander J. [1 ]
Gorelik, Seth [1 ,2 ]
Nally, Laura M. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Bowdoin Coll, Brunswick, ME USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
type; 1; diabetes; stage; 2; 3; teplizumab; disease-modifying therapies; ANTI-CD3; MONOCLONAL-ANTIBODY; C-PEPTIDE RESPONSES; DOUBLE-BLIND; ONSET; TEPLIZUMAB; IDENTIFICATION; PATHOGENESIS; USTEKINUMAB; AUTOANTIGEN; INHIBITOR;
D O I
10.3389/fendo.2024.1477101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new diagnosis of type 1 diabetes (T1D) may be accompanied by numerous lifelong financial, emotional, and physical challenges, thus advancements in therapies that can delay the onset of clinical disease are crucial. T1D is an autoimmune condition involving destruction of pancreatic beta cells leading to insulin deficiency, hyperglycemia, and long-term insulin dependence. The pathogenesis of T1D is classified into stages, with the first signal being the detection of autoantibodies without any glycemic changes. In the second stage, dysglycemia develops without symptoms, and in stage 3, symptoms of hyperglycemia become apparent, and at this time a clinical diagnosis of T1D is made. As a greater understanding of these stages of T1D have evolved, research efforts have been devoted to delaying the onset of clinical disease. To date, only one medication, teplizumab, has been approved by the Food and Drug Administration (FDA) for the treatment of stage 2 T1D. This narrative review present published trials and ongoing research on disease modifying therapies (DMT) in T1D, the mechanisms of action for each therapy, and the stages of T1D that these interventions are being studied.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
    Kroger, Charles J.
    Clark, Matthew
    Ke, Qi
    Tisch, Roland M.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [22] Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis
    Liu, Yuting
    Li, Weixia
    Chen, Yu
    Wang, Xin
    ENDOCRINE, 2024, 83 (02) : 322 - 329
  • [23] A Narrative Review of Celiac Disease in India with a Focus on its Link with Type 1 Diabetes
    Tharunika, Sridhar
    Mohan, Viswanathan
    Anjana, Ranjit Mohan
    Amutha, Anandakumar
    JOURNAL OF DIABETOLOGY, 2025, 16 (01) : 14 - 21
  • [24] Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
    Vazquez, Luis Alberto
    Romera, Irene
    Rubio-de Santos, Miriam
    Escalada, Javier
    DIABETES THERAPY, 2023, 14 (11) : 1771 - 1784
  • [25] Life and death of β cells in Type 1 diabetes: A comprehensive review
    Wilcox, Nicholas S.
    Rui, Jinxiu
    Hebrok, Matthias
    Herold, Kevan C.
    JOURNAL OF AUTOIMMUNITY, 2016, 71 : 51 - 58
  • [26] Adjunct therapies in treatment of type 1 diabetes
    Goyal, Itivrita
    Sattar, Alamgir
    Johnson, Megan
    Dandona, Paresh
    JOURNAL OF DIABETES, 2020, 12 (10) : 742 - 753
  • [27] Coaggregation of Asthma and Type 1 Diabetes in Children: A Narrative Review
    Sgrazzutti, Laura
    Sansone, Francesco
    Attanasi, Marina
    Di Pillo, Sabrina
    Chiarelli, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [28] Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes
    Anderson, Randy L.
    DiMeglio, Linda A.
    Mander, Adrian P.
    Dayan, Colin M.
    Linsley, Peter S.
    Herold, Kevan C.
    Marinac, Marjana
    Ahmed, Simi T.
    DIABETES CARE, 2022, 45 (10) : 2189 - 2201
  • [29] Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes
    Tatovic, Danijela
    Dayan, Colin M.
    DIABETIC MEDICINE, 2021, 38 (12)
  • [30] Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report
    Wherrett, Diane K.
    Chiang, Jane L.
    Delamater, Alan M.
    DiMeglio, Linda A.
    Gitelman, Stephen E.
    Gottlieb, Peter A.
    Herold, Kevan C.
    Lovell, Daniel J.
    Orchard, Trevor J.
    Ryan, Christopher M.
    Schatz, Desmond A.
    Wendler, David S.
    Greenbaum, Carla J.
    DIABETES CARE, 2015, 38 (10) : 1975 - 1985